Hyloris Pharmaceuticals (LTS:0AB6) EBITDA Margin % : -522.91% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hyloris Pharmaceuticals's EBITDA for the six months ended in Dec. 2023 was €-8.65 Mil. Hyloris Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was €1.65 Mil. Therefore, Hyloris Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2023 was -522.91%.

Hyloris Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Hyloris Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals EBITDA Margin % Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-2,269.23

-3,184.00

-342.76

-350.76

-533.76

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial							-120.02	-409.39	-319.19	-549.22	-522.91

Competitive Comparison of Hyloris Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Hyloris Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's EBITDA Margin % falls into.

Hyloris Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Hyloris Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-15.02	/	2.814
	=	-533.76 %

Hyloris Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-8.649	/	1.654
	=	-522.91 %

Hyloris Pharmaceuticals (LTS:0AB6) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Hyloris Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

52U:Germany HYL:Belgium

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (LTS:0AB6) Headlines

No Headlines